Literature DB >> 30798446

Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come.

Elizabeth A Mittendorf1, Tari A King2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30798446     DOI： 10.1245/s10434-019-07240-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  6 in total

1.  The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis.

Authors:  Roi Weiser; Waqar Haque; Efstathia Polychronopoulou; Sandra S Hatch; Yong-Fang Kuo; William J Gradishar; V Suzanne Klimberg
Journal:  Breast Cancer Res Treat       Date:  2020-10-18       Impact factor: 4.872

2.  Impact of the 21-gene recurrence score assay on chemotherapy decision making and outcomes for breast cancer patients with four or more positive lymph nodes.

Authors:  Qing-Hong Zhang; Wen-Wen Zhang; Jun Wang; Chen-Lu Lian; Jia-Yuan Sun; Zhen-Yu He; San-Gang Wu
Journal:  Ann Transl Med       Date:  2019-09

Review 3.  Genomic Assays in Node Positive Breast Cancer Patients: A Review.

Authors:  Maroun Bou Zerdan; Maryam Ibrahim; Clara El Nakib; Rayan Hajjar; Hazem I Assi
Journal:  Front Oncol       Date:  2021-02-16       Impact factor: 6.244

4.  How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients.

Authors:  Xiaofu Zhu; Susan Dent; Lise Paquet; Tinghua Zhang; Daniel Tesolin; Nadine Graham; Olexiy Aseyev; Xinni Song
Journal:  Curr Oncol       Date:  2021-02-04       Impact factor: 3.677

5.  The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1-3 node positive breast cancer.

Authors:  Yogeshkumar Malam; Mohamed Rabie; Konstantinos Geropantas; Susanna Alexander; Simon Pain; Mina Youssef
Journal:  Cancer Rep (Hoboken)       Date:  2021-10-19

6.  Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX.

Authors:  Aditya K Sengupta; Aparna Gunda; Sukriti Malpani; Chandra Prakash V Serkad; Chetana Basavaraj; Ashok Bapat; Manjiri M Bakre
Journal:  Cancer Med       Date:  2020-10-07       Impact factor: 4.452
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.